Characterization of Genetic Variants in the SLC5A5 Gene and Associations With Breast Milk Iodine Concentration in Lactating Women of African Descent: The NUPED Study

listen audio

Study Justification:
This study aimed to investigate the role of genetic variants in the SLC5A5 gene in relation to the transfer of iodine from plasma into breast milk in lactating women of African descent. This research is important because it explores a previously unexplored area of study and provides insights into the inter-individual variability in breast milk iodine concentration (BMIC). Understanding the genetic factors influencing BMIC can have implications for maternal and infant health, as iodine is essential for proper thyroid function and neurodevelopment.
Highlights:
– The study identified and characterized genetic variants in the SLC5A5 gene in women of African descent living in urban South Africa.
– A significant difference in BMIC was observed between different genotypes of the rs775249401 variant, suggesting that genetic variations in the SLC5A5 gene may play a role in the transfer of iodine into breast milk.
– The study found that A-allele carriers of rs775249401(AG+AA) are likely to have higher iodine transfer into breast milk compared to the homozygous GG counterparts.
– These findings suggest that genetic factors contribute to the inter-individual variability in BMIC and may partially explain inadequate iodine intake in lactating women.
Recommendations:
– Further research is needed to validate these findings in larger and more diverse populations.
– Future studies should explore the functional implications of the identified genetic variants and their impact on iodine transport mechanisms.
– Public health interventions should consider genetic factors when designing strategies to improve iodine status in lactating women, especially those of African descent.
Key Role Players:
– Researchers and scientists specializing in genetics, nutrition, and maternal and child health.
– Healthcare professionals, including obstetricians, pediatricians, and lactation consultants.
– Policy makers and public health officials responsible for developing and implementing strategies to improve maternal and infant health.
Cost Items for Planning Recommendations:
– Research funding for conducting larger-scale studies and genetic analyses.
– Laboratory equipment and supplies for genetic sequencing and genotyping.
– Recruitment and enrollment of study participants.
– Data collection and analysis.
– Dissemination of research findings through publications and conferences.
– Development and implementation of public health interventions and educational programs.
Please note that the cost items provided are general categories and may vary depending on the specific context and resources available.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is relatively strong, but there are some areas for improvement. The study design is a prospective cohort study, which provides a higher level of evidence compared to other study designs. The sample size is adequate, with 250 enrolled pregnant women and 55 lactating women included in the analysis. The study also includes genetic sequencing and genotyping, which adds to the strength of the evidence. However, there are a few areas for improvement. First, the abstract does not provide information on the representativeness of the study sample, which could affect the generalizability of the findings. Second, the statistical analysis methods used are not clearly described, making it difficult to assess the validity of the results. Finally, the abstract does not mention any potential limitations of the study, which is important for interpreting the findings. To improve the evidence, the authors could provide more details on the representativeness of the study sample, clearly describe the statistical analysis methods used, and discuss any limitations of the study.

Background: The sodium iodide symporter is responsible for the transfer of iodine into breast milk and is encoded for by the SLC5A5 gene. The role of genetic variants in the SLC5A5 gene locus in relation to the transfer of iodine from plasma into breast milk in healthy lactating individuals has, to our knowledge, not been explored. Objective: To identify and characterize possible genetic variants of the SLC5A5 gene in women of African descent living in urban South Africa, and to study associations with breast milk iodine concentrations (BMIC) in lactating women. Methods: This study is affiliated to the Nutrition during Pregnancy and Early Development (NuPED) cohort study (n = 250 enrolled pregnant women). In a randomly selected sub-sample of 32 women, the SLC5A5 gene was sequenced to identify known and novel variants. Of the identified variants, genotyping of selected variants was performed in all pregnant women who gave consent for genetic analyses (n = 246), to determine the frequency of the variants in the study sample. Urinary iodine concentration (UIC) in spot urine samples and BMIC were measured to determine iodine status. Associations of SLC5A5 genetic variants with BMIC were studied in lactating women (n = 55). Results: We identified 27 variants from sequencing of gene exomes and 10 variants were selected for further study. There was a significant difference in BMIC between the genotypes of the rs775249401 variant (P = 0.042), with the homozygous GG group having lower BMIC [86.8 (54.9–167.9) μg/L] compared to the (A) allele carriers rs775249401(AG+AA) [143.9 (122.4–169.3) μg/L] (P = 0.042). Of the rs775249401(GG), 49% had UIC <100 μg/L and 61% had BMIC <100 μg/L. On the other hand, 60% of the rs775249401(AG+AA) carriers had UIC <100 μg/L, and none had a BMIC <100 μg/L. Conclusion: Our results suggest that A-allele carriers of rs775249401(AG+AA) are likely to have higher iodine transfer into breast milk compared to the homozygous GG counterparts. Thus, genetic variations in the SLC5A5 gene may play an important role in the transfer of iodine from plasma into breast milk and may partially explain inter-individual variability in BMIC.

The NuPED study was a prospective cohort study conducted in Johannesburg, South Africa from March 2016 to July 2018. The study protocol has be previously published (14). In brief, pregnant women (n = 250) were enrolled if they were between 18 and 39 years of age, <18 weeks gestational age, born in South Africa or a neighboring country, have lived in Johannesburg for at least 12 months, were able to communicate effectively in one of the local languages, non-smoking, and expecting a singleton. Pregnant women were excluded from participation if they reported use of illicit drugs, had a known non-communicable disease such as diabetes, renal disease, history of high blood cholesterol and hypertension, and had a known infectious disease such as tuberculosis or hepatitis, or known serious illness such as cancer, lupus or psychosis. HIV positive women were included in the study. Pregnant women were assessed at 10 and quality score of >500 frets were met. The sequence files were aligned against Genome Reference Consortium Human Build 37 (hg19), followed by coverage analysis and variant calling using the coverage analysis and variantCaller plugins from the Torrent Suite, respectively. Secondary data analyses of the variant caller files were annotated, filtered and mined following an in-house pipeline (15). In the subset of 32 sequenced samples, variants that passed the quality control assessment were considered for validation in the entire sample set using the iPLEX® MassARRAY system from Agena Bioscience™. IPLEX assays were designed and analyses were performed by the service provider Inqaba Biotech (Inqaba Biotechnology Pretoria South Africa). Assays were designed using the Assay Design Suite (ADS) software and dbSNP for metadata. gDNA was amplified in 96 microtiter plates using iPLEX reagent kits and a nano dispenser RS1000 was used to transfer samples from microtiter plates to a SpectroCHIP® array. Data were obtained from the SpectroCHIP® array using the MassARRAY® analyser. Reports were automatically generated by Typer (Company). Genotype calls were made in real-time during MALDI-TOF analysis and data was automatically saved to the MassARRAY database. Variants were assessed for quality, and tested for adherence to Hardy-Weinberg equilibrium (HWE) (16) by using Haploview and modified Pearson chi-square (χ2) test. Adherence to HWE was set at P < 0.001. From the 98 women participating in the 6-month follow-up, we collected a midstream spot urine sample (10–40 ml) into clean polystyrene cups between 07:00 and 12:00 noon, and approximately 5 ml was decanted into iodine-free screw-capped cups. The research team ensured that the urine samples were not used for any routine assessments using dipsticks (potential contamination with iodine). Samples were aliquoted and stored on-site at −20°C for a maximum of 7 days. Thereafter, samples were transported on dry ice to the CEN laboratories, for storage at −80°C until analysis. Urinary iodine concentration (UIC) in spot urine samples was measured in duplicate using the Pino modification of the Sandell-Kolthoff reaction with spectrophotometric detection at CEN laboratories (17, 18). All analyses were done using nanopure grade water and all laboratory glassware and plasticware were acid washed before use. Internal and external controls were used to ensure the quality of the analysis. Iodine concentrations in spot urine samples are expressed as median concentrations (μg/L). A UIC cut-off of <100 μg/L was used to indicate insufficient iodine intake in lactating women (19). From 58 lactating women who participated in the 6-month follow-up, a breast milk (foremilk) sample (≈5 ml) was collected by manual expression into an iodine-free screw-capped cup before feeding the infant. Iodine concentrations in breast milk (in μg/L) were measured using a multi-collector inductively coupled plasma mass spectrometer [MC-ICP-MS (Finnigan NEPTUNE, Thermo Scientific™ Waltham, MA, USA)] as described by Dold et al. (10). A BMIC cut-off of 500 μg/L) were considered outliers. These UIC outliers (n = 2) were excluded from the analysis because high intakes of iodine have previously been reported to lead to improved BMIC in an individual that harbored a SLC5A5 variant associated with the lower transfer of iodine into breast milk (23). Normally and non-normally distributed data are expressed as means ± standard deviation (SD) and medians (25th percentile, 75th percentile), respectively. Categorical data are expressed as frequencies and percentages. Participants were stratified according to UIC categories (UIC <100 μg/L and UIC ≥100 μg/L) or BMIC categories (BMIC <100 μg/L and BMIC ≥100 μg/L). The between-group analyses were performed using the Mann Whitney U test. Overlaid scatterplots were used to depict the relationship between total daily iodine excretion, fractional iodine excretion in breast milk and fractional iodine excretion in urine. Unadjusted general linear models were performed to compare UIC and BMIC between genetic variants with the recessive genetic model (GG vs. GA + AA) as categorical variables. For the significant models, effect sizes were calculated using Cohens' d and partial eta squared. Significance was set at p < 0.05.

N/A

The study titled “Characterization of Genetic Variants in the SLC5A5 Gene and Associations With Breast Milk Iodine Concentration in Lactating Women of African Descent: The NUPED Study” explores the role of genetic variants in the SLC5A5 gene in relation to the transfer of iodine from plasma into breast milk in lactating women. The study aims to identify and characterize possible genetic variants of the SLC5A5 gene in women of African descent living in urban South Africa and study associations with breast milk iodine concentrations (BMIC).

The study conducted next-generation sequencing of the SLC5A5 gene in a subset of 32 women and identified 27 variants. Ten variants were selected for further study, and genotyping of these variants was performed in all pregnant women enrolled in the study (n = 246) to determine the frequency of the variants in the sample.

Urinary iodine concentration (UIC) in spot urine samples and BMIC were measured to determine iodine status. Associations of SLC5A5 genetic variants with BMIC were studied in lactating women (n = 55). The study found a significant difference in BMIC between the genotypes of the rs775249401 variant, with the homozygous GG group having lower BMIC compared to the (A) allele carriers rs775249401(AG+AA).

The study suggests that A-allele carriers of rs775249401(AG+AA) are likely to have higher iodine transfer into breast milk compared to the homozygous GG counterparts. These findings indicate that genetic variations in the SLC5A5 gene may play an important role in the transfer of iodine from plasma into breast milk and may partially explain inter-individual variability in BMIC.

The study was conducted as part of the Nutrition during Pregnancy and Early Development (NuPED) cohort study, which enrolled pregnant women in Johannesburg, South Africa. The study protocol included assessments at different gestational ages and follow-up assessments in the women and their infants after birth.

Ethical approval was obtained for the study, and participants provided written informed consent. Venous blood samples were collected for genomic DNA isolation, and next-generation sequencing was performed using the Ion Torrent platform. Urine and breast milk samples were collected for measurement of UIC and BMIC, respectively. Data analysis and statistical analysis were conducted to assess associations between genetic variants and iodine concentrations.

In conclusion, the study highlights the potential role of genetic variants in the SLC5A5 gene in the transfer of iodine from plasma into breast milk. These findings contribute to our understanding of inter-individual variability in BMIC and may have implications for improving access to maternal health by identifying genetic factors that influence iodine transfer during lactation.
AI Innovations Description
The study titled “Characterization of Genetic Variants in the SLC5A5 Gene and Associations With Breast Milk Iodine Concentration in Lactating Women of African Descent: The NUPED Study” explores the role of genetic variants in the SLC5A5 gene in relation to the transfer of iodine from plasma into breast milk in lactating women. The study aims to identify and characterize possible genetic variants of the SLC5A5 gene in women of African descent living in urban South Africa and study their associations with breast milk iodine concentrations (BMIC).

The study was conducted as part of the Nutrition during Pregnancy and Early Development (NuPED) cohort study, which enrolled 250 pregnant women in Johannesburg, South Africa. The women were between 18 and 39 years of age,
AI Innovations Methodology
The study titled “Characterization of Genetic Variants in the SLC5A5 Gene and Associations With Breast Milk Iodine Concentration in Lactating Women of African Descent: The NUPED Study” aims to explore the role of genetic variants in the SLC5A5 gene in relation to the transfer of iodine from plasma into breast milk in lactating women of African descent living in urban South Africa. The study conducted genetic sequencing of the SLC5A5 gene in a subset of 32 women and genotyped selected variants in all pregnant women enrolled in the NuPED study (n = 246). Urinary iodine concentration (UIC) and breast milk iodine concentration (BMIC) were measured to determine iodine status. Associations between SLC5A5 genetic variants and BMIC were studied in a subset of 55 lactating women.

To simulate the impact of recommendations on improving access to maternal health, a methodology could be developed as follows:

1. Identify potential recommendations: Review existing literature and consult with experts in the field to identify potential recommendations for improving access to maternal health. These recommendations could include interventions such as increasing the number of healthcare facilities, improving transportation infrastructure, implementing telemedicine services, providing training for healthcare providers, and increasing awareness and education about maternal health.

2. Define indicators: Determine the indicators that will be used to measure the impact of the recommendations on improving access to maternal health. These indicators could include metrics such as the number of healthcare facilities per capita, average travel time to the nearest healthcare facility, the number of telemedicine consultations conducted, the number of healthcare providers trained, and changes in awareness and knowledge about maternal health.

3. Collect baseline data: Gather baseline data on the current state of maternal health access in the target population. This could involve conducting surveys, interviews, or data analysis to assess the existing healthcare infrastructure, transportation options, availability of telemedicine services, healthcare provider capacity, and community awareness and knowledge about maternal health.

4. Develop a simulation model: Create a simulation model that incorporates the potential recommendations and their expected impact on the defined indicators. This model could be developed using statistical software or simulation tools and should consider factors such as population size, geographical distribution, healthcare facility capacity, transportation networks, and community characteristics.

5. Run simulations: Use the simulation model to run various scenarios that reflect the implementation of different combinations of recommendations. Each scenario should simulate the impact of the recommendations on the defined indicators. The simulations could be run multiple times to account for uncertainty and variability in the data.

6. Analyze results: Analyze the results of the simulations to assess the potential impact of the recommendations on improving access to maternal health. Compare the outcomes of different scenarios to identify the most effective combination of recommendations.

7. Refine and validate the model: Refine the simulation model based on the analysis of the results and feedback from experts in the field. Validate the model by comparing the simulated outcomes with real-world data, if available.

8. Communicate findings: Present the findings of the simulation study in a clear and concise manner, highlighting the potential impact of the recommendations on improving access to maternal health. Share the results with relevant stakeholders, such as policymakers, healthcare providers, and community organizations, to inform decision-making and implementation strategies.

By following this methodology, researchers and policymakers can gain insights into the potential impact of different recommendations on improving access to maternal health and make informed decisions about resource allocation and intervention strategies.

Share this:
Facebook
Twitter
LinkedIn
WhatsApp
Email
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.